Business Context and Reporting Period
This Form 8-K was filed by Inpixon (not XTI Aerospace, Inc.) on February 20, 2019. The report details a material definitive agreement entered into on the same date to settle an arbitration award involving the Company, its subsidiary Sysorex, Inc., and Atlas Technology Group, LLC.
Key Financial Metrics and Transaction Details
- Original Arbitration Award: $1,156,840.25 plus $59,955.28 in pre-judgment interest.
- Settlement Reduction: Atlas agreed to reduce the award by $275,000.
- Net Award Value: $941,795.53.
- Settlement Consideration: 749,440 shares of freely-tradable common stock issued to Atlas.
- Share Valuation Basis: Calculated using 120% of the Net Award divided by a minimum price of $1.508 per share.
- Liability Sharing: Following a prior spin-off, Sysorex is obligated to indemnify Inpixon for 50% of the total amount paid to satisfy the award.
- Outstanding Equity (as of Feb 20, 2019): 5,627,161 common shares; 1 Series 4 Convertible Preferred share (convertible to 202 common); 2,254 Series 5 Convertible Preferred shares (convertible to ~676,877 common).
Material Changes and Unusual Items
The primary material change is the resolution of a legal dispute through the issuance of equity rather than cash. The filing notes that if Atlas sells the Settlement Shares for proceeds exceeding the Net Award value, the excess must be delivered to legal counsel to offset arbitration fees. The filing text does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period.
Guidance, Outlook, and Risks
The closing of the settlement is expected to occur on or about February 21, 2019. Upon issuance of the shares, the award will be deemed satisfied in full, and all parties will release claims arising from the original engagement agreement. The shares are being issued pursuant to an effective Form S-3 registration statement, with a prospectus supplement filed concurrently. No forward-looking financial guidance or specific risk factors beyond the settlement terms are provided in this document.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-issuance of the 749,440 Settlement Shares.
- Confirm the dilution impact on existing shareholders given the issuance of freely-tradable stock.
- Review the Separation and Distribution Agreement to understand the mechanics of Sysorex's 50% indemnification obligation.
- Check the prospectus supplement filed on February 20, 2019, for details on the settlement shares.
- Monitor for any future filings regarding the sale of Settlement Shares by Atlas and the potential remittance of excess proceeds to legal counsel.